Industry News

Nutrition 21 to Enter Cough/Cold Market

December 1, 2010

Expanding its product portfolio, Nutrition 21, Inc., Purchase, NY, has received an exclusive license in the U.S. from Denmark-based Provita Development ApS for Coldizin, an ingredient combination patented in the U.S. and Europe for enhancing upper-respiratory health. A patent is pending in Canada. The exclusive license allows Nutrition 21 to expand its product portfolio with a novel, clinically substantiated ingredient for the $4.5 billion U.S. cough and cold category. “Coldizin is a clinically substantiated product that shows significant results in helping people deal with upper respiratory symptoms. Its innovative blend of the bioflavonoid troxerutin and zinc provides an option for either the dietary supplement or homeopathic segments,” said William Levi, vice president, Ingredients and Special Markets, Nutrition 21.
  • Oral Solid Dosage Outsourcing: Trends & Challenges

    Oral Solid Dosage Outsourcing: Trends & Challenges

    Tim Wright, Editor, Contract Pharma||March 1, 2017
    Despite the increasing number of biologics, oral solids remain the dominant dosage form in the pharmaceutical market.

  • Skeleton Crew: Solutions for Bone Health

    Skeleton Crew: Solutions for Bone Health

    Lisa Schofield, Contributing Writer||March 1, 2017
    Products that can help aging populations stay active and independent will be in a strong market position.

  • Formulation Strategies for  Aging Consumers

    Formulation Strategies for Aging Consumers

    Stephen Tindal, Director, Science and Technology, Catalent Pharma Solutions||March 1, 2017
    Convenience, flavor and novel combinations of ingredients can help offer better product experiences.